Clinical trial

Chemotherapy Plus Gefitinib for Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomized Controlled Trial

NCT02951637

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2016-12-01

PhasePHASE2

Study timeline

Study start (unknown)2016-12-01Date precision: month

Registry last updated2016-11-01

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Lung Adenocarcinomaunresolved

Interventions

Pemetrexed plus carboplatin combined with gefitinibDRUG

GefitinibDRUG · verified · RxNorm: gefitinib

Sponsors & collaborators

Shanghai Chest Hospitallead sponsor

Ruijin Hospitalcollaborator

Changhai Hospitalcollaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02951637 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.